Published in Proc Natl Acad Sci U S A on November 07, 1995
The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol (2005) 4.54
Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med (2007) 4.36
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Mechanisms and management of retinopathy of prematurity. N Engl J Med (2012) 3.52
Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc (2009) 3.31
Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol (2001) 3.26
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol (1997) 2.73
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A (1996) 2.67
The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci (2010) 2.61
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest (2004) 2.45
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol (2000) 2.41
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A (2001) 2.35
Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A (1997) 2.32
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res (2010) 2.30
Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol (1997) 2.28
HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J (2003) 2.28
Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (2012) 2.19
Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol (2002) 2.12
Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med (2009) 2.12
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest (1999) 2.08
Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood (2011) 2.02
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol (2000) 1.95
POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. Retina (2016) 1.93
Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest (2007) 1.89
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol (2007) 1.88
Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circ Res (2009) 1.86
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest (2005) 1.84
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A (2001) 1.83
Retinopathy of prematurity. Lancet (2013) 1.82
Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest (2012) 1.79
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest (1996) 1.76
Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci (2008) 1.76
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol (2005) 1.69
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A (2004) 1.67
Ocular neovascularization. J Mol Med (Berl) (2013) 1.65
Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol (2001) 1.64
5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids. Sci Transl Med (2011) 1.63
IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res (2006) 1.61
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 1.59
Vascular endothelial growth factor and ocular neovascularization. Am J Pathol (1997) 1.56
Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr (2011) 1.50
Computer-aided quantification of retinal neovascularization. Angiogenesis (2009) 1.50
Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest (2003) 1.50
Cystoid macular edema. Clin Ophthalmol (2008) 1.47
PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood (2010) 1.46
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol (2008) 1.45
Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization. Vasc Cell (2011) 1.44
In silico cloning of novel endothelial-specific genes. Genome Res (2000) 1.42
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Retinopathy of prematurity. Lancet (1991) 1.39
Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med (2008) 1.36
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol (1999) 1.34
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34
A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes (2009) 1.33
Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci (2011) 1.33
Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci (2005) 1.32
Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31
Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia (2010) 1.31
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol (2013) 1.30
Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol (1997) 1.29
Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol (1996) 1.26
A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics (2011) 1.23
Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest (2001) 1.20
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A (2002) 1.20
Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol (1998) 1.20
Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A (2002) 1.19
Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One (2008) 1.17
Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci U S A (2001) 1.17
Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia (2010) 1.15
Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol (2000) 1.13
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
A new gamma-interferon-inducible promoter and splice variants of an anti-angiogenic human tRNA synthetase. Nucleic Acids Res (2004) 1.13
EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol (2006) 1.11
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev (2014) 1.09
PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci U S A (2010) 1.08
An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. Proc Natl Acad Sci U S A (2001) 1.07
The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci (2009) 1.07
Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol (1999) 1.05
Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol (1997) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest (1996) 1.03
The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J (1996) 1.03
Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients. J Res Med Sci (2012) 1.03
VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am J Pathol (2012) 1.02
New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis (2014) 1.02
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther (2010) 1.02
Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis (2011) 1.01
Balance of pro- and anti-inflammatory cytokines correlates with outcome of acute experimental Pseudomonas aeruginosa keratitis. Infect Immun (2002) 1.01
Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol (2001) 1.01
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med (2014) 1.00
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One (2012) 1.00
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci (1994) 10.46
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol (1954) 5.98
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A (1995) 5.66
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev (1992) 5.50
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell (1992) 4.90
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun (1993) 2.56
Diode laser photocoagulation for retinopathy of prematurity. Preliminary results. Arch Ophthalmol (1992) 2.24
Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest (1985) 2.00
A monoclonal antibody (3G5)-defined ganglioside antigen is expressed on the cell surface of microvascular pericytes. J Exp Med (1988) 1.55
Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes (1995) 1.35
Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci (1994) 1.31
Oxygen and diabetic eye disease. Graefes Arch Clin Exp Ophthalmol (1990) 1.29
Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol (1991) 1.23
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care (2001) 9.76
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A (2005) 7.12
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? J Virol (2005) 5.78
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A (1995) 5.66
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Genetic diversity and disease control in rice. Nature (2000) 5.34
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (1990) 5.33
Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell (2000) 5.08
Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell (1999) 5.07
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Crystal structure of a TFIIB-TBP-TATA-element ternary complex. Nature (1995) 4.93
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A (2006) 4.49
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
A transcriptional switch mediated by cofactor methylation. Science (2001) 4.32
Superconductivity at 43 K in SmFeAsO1-xFx. Nature (2008) 3.80
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg (1996) 3.76
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes. Cell (1998) 3.62
Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology (2006) 3.59
Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. Cell (2000) 3.59
Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions. Science (1997) 3.59
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol (2005) 3.51
Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol (1996) 3.49
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Diabetic retinopathy. Diabetes Care (1998) 3.39
Prevalence and genetic diversity of coronaviruses in bats from China. J Virol (2006) 3.37
A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell (1999) 3.36
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest (1999) 3.18
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14
The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol (2007) 3.12
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 3.08
CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene (2011) 3.08
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 2.93
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 2.80
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
An intrinsic bond-centered electronic glass with unidirectional domains in underdoped cuprates. Science (2007) 2.76
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med (1998) 2.64
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
Microbial alkaline proteases: from a bioindustrial viewpoint. Biotechnol Adv (1999) 2.63
The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol (1991) 2.63
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature (2000) 2.57
Light-induced superconductivity in a stripe-ordered cuprate. Science (2011) 2.54
Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol (1997) 2.51
Phenotypes Associated with SHOX Deficiency. J Clin Endocrinol Metab (2001) 2.51
Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A (1992) 2.48
Evolution and molecular epidemiology of H9N2 influenza A viruses from quail in southern China, 2000 to 2005. J Virol (2006) 2.47
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A (1989) 2.45
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Receptor-mediated transport of insulin across endothelial cells. Science (1985) 2.42
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem (2001) 2.42
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest (1996) 2.36
Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene (2011) 2.36
Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol (1995) 2.35
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A (2001) 2.35
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Systematic review and meta-analysis of the early and late outcomes of open and endovascular repair of abdominal aortic aneurysm (Br J Surg 2013; 100: 863-872). Br J Surg (2013) 2.33
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A (1996) 2.31
Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect (2011) 2.29
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29